| Title |
Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea—experience from 110 patients
|
|---|---|
| Published in |
Annals of Hematology, September 2013
|
| DOI | 10.1007/s00277-013-1893-z |
| Pubmed ID | |
| Authors |
Kihyun Kim, Seok Jin Kim, Verena Voelter, Cheolwon Suh, Sung-Soo Yoon, Je-Jung Lee, Jae-Yong Kwak, Hun-Mo Ryoo, Yang Soo Kim, Joon Ho Moon, Seong Kyu Park, Sung-Hyun Kim, Yeung-Chul Mun, Jin Seok Kim, Hyeon-Seok Eom, Deog-Yeon Jo, Hyun Jung Jun, Ki-Hwan Kim, Jeong-Ok Lee, Jae Hoon Lee, Chang-Ki Min, Korean Multiple Myeloma Working Party (KMMWP) |
| Abstract |
We conducted a retrospective analysis of lenalidomide with dexamethasone for patients with relapsed/refractory multiple myeloma (RRMM) who were treated within the Korean patient access program. Lenalidomide has been approved for RRMM for several years in Europe and North America, but has not been accessible to Asian patients in the past. Between 2008 and 2012, 110 patients from 20 hospitals were enrolled. The overall response rate (ORR) was 43.6 % with 15.4 % of very good partial response (VGPR) or better. The median time to progression (TTP) in this heavily pretreated patient population was 8.0 months, and median overall survival (OS) was 23 months. Hematologic toxicities, fatigue, anorexia, and constipation were the most common adverse events. The number of previous treatment lines, previous exposure to thalidomide, refractoriness to thalidomide and bortezomib, pretreatment white blood cell count (WBC), platelet count, t(14;16), and 17p deletion were significant prognostic factors for TTP, and creatinine clearance, refractoriness to thalidomide and bortezomib, performance status, platelet count, and 17p deletion were significant for OS in univariate analysis. In multivariate analysis, WBC and platelet count were significant prognostic factors for TTP and performance status for OS. For Korean myeloma patients, lenalidomide showed considerable efficacy, and toxicities were comparable to the data published in Europe and North America. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 40 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Croatia | 1 | 3% |
| United States | 1 | 3% |
| Brazil | 1 | 3% |
| Unknown | 37 | 93% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 9 | 23% |
| Other | 7 | 18% |
| Student > Ph. D. Student | 5 | 13% |
| Student > Master | 5 | 13% |
| Professor | 2 | 5% |
| Other | 4 | 10% |
| Unknown | 8 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 30% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 15% |
| Psychology | 5 | 13% |
| Nursing and Health Professions | 3 | 8% |
| Agricultural and Biological Sciences | 1 | 3% |
| Other | 3 | 8% |
| Unknown | 10 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 September 2013.
All research outputs
#18,347,414
of 22,721,584 outputs
Outputs from Annals of Hematology
#1,439
of 2,163 outputs
Outputs of similar age
#147,727
of 198,485 outputs
Outputs of similar age from Annals of Hematology
#24
of 32 outputs
Altmetric has tracked 22,721,584 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,163 research outputs from this source. They receive a mean Attention Score of 4.1. This one is in the 21st percentile – i.e., 21% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 198,485 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 32 others from the same source and published within six weeks on either side of this one. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.